TAMPA, Fla.—The biopharmaceutical company Oragenics Inc. was issued patent number 7931892 from the United States Patent and Trademark office for its proprietary blend of naturally occurring oral bacteria ProBiora3®, which has been shown to produce a wide range of oral-care benefits. ProBiora3 contains three strains of beneficial oral bacteria that help maintain a healthy microbial balance in the mouth. It is 100-percent natural and is made in the United States in an FDA-registered and GMP-certified facility.
Issuance of the patent enables Oragenics to immediately pursue global private label and licensing opportunities in major product categories. The market size of these channels collectively exceeds $170 billion. Product suppliers in these categories, ranging from those with well established brands to newer market entrants, will be able to achieve newfound product differentiation with ProBiora3, as its beneficial characteristics provide a meaningful value added benefit to consumers.
ProBiora3 technology was developed by Oragenics’ chief scientific officer Jeffrey Hillman D.M.D., Ph.D., during more than 25 year of research, which began at the Harvard affiliated Forsyth Institute in Boston and was fully developed at Oragenics. This technology is currently available in Oragenics’ line of probiotic products for oral care for the entire family, including EvoraPro®, EvoraPlus®, EvoraKids®, EvoraPet™ and Teddy’s Pride™.
“The concept behind ProBiora3 takes advantage of the observation that not all bacteria are bad," Hillman said. “In a complex environment like the mouth, we predicted we would find certain types of bacteria that are associated with healthy teeth and gums. Finding these bacteria and using them to create ProBiora3 is the first of several innovative technologies discovered from oral biology, which Oragenics plans to bring to the marketplace."
Probiora3 has the potential to be a beneficial ingredient for a wide range of product categories and applications, such as toothpaste, rinses and floss.